Lanean...
Antiviral cell therapy: is this the future?
In this issue of Blood, Leen and colleagues report the first multicenter trial of third-party viral-specific T cells (VSTs) for the treatment of 50 patients with refractory viral infections (cytomegalovirus, adenovirus, and Epstein-Barr virus) after stem cell transplantation.(1)
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society of Hematology
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3695358/ https://ncbi.nlm.nih.gov/pubmed/23813935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-05-500082 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|